Kawasaki
Innovation Gateway

Ikuta Ryokuchi:
Full of natural greenery

Kawasaki Fujiko F. Fujio Museum

Kawasaki Daishi
(Heiken-ji Temple)

The costal area adjacent to
Haneda International Airport

Musashi Kosugi District:
A region lined by high-rise condominiums/apartment buildings

The magical night-time view of
Kawasaki's coastal factories

川崎市
KAWASAKI CITY

A Highly Convenient and Vibrant City



Located in the center of the National Capital Region, the city has good accessibility via land, air, and sea



Population: 1,503,301 per.
(As of Sep. 1, 2017)

Area: 144.35 km^2

Gross City Product:
5.1386 trillion yen (FY2013)
* Equivalent to the Gross Domestic Product of Luxembourg

Vibrant City Blessed with an Abundance of Human Resources

<2016 Comparative Statistics of Major Japanese Cities>

- Birth rate — Ranked 1st
- Average age — Ranked 1st
- Percentage of population of working-age — Ranked 1st
- Shipment value of manufactured goods per employee — Ranked 1st
- Percentage of workers employed by academic/research and development institutions — Ranked 1st

(Provisional calculation by Kawasaki City based on categorization of business establishments)

Global Companies Located in Kawasaki City

Over 400 R&D organizations,

and over 1,200 SMEs in Kawasaki,



KING SKYFRONT

Manufacturing function to R&D function

Before 2000　ISUZU was promoting business restructuring.

2001 Mar.　Urban Renaissance Agency get the land of ISUZU.

2004 May　ISUZU moved the Kawasaki factory to Fujisawa city.

2008 Sep.　KAWASAKI city government formulate participation arrangement policy of TONOMACHI 3-chome.

2010 Mar.　TONOMACHI 3-chome Land Readjustment Project began.

2011 Mar.　TONOMACHI 3-chome named as **"KING SKYFRONT".**

2011 Jul.　Central Institute for Experimental Animals (CIEA)　started operation.

2011 Dec.　Designated as a Special Zone for International Competitiveness Development.

National Special Zones for life science

1. Special Zone for International Competitiveness Development （December 2011）

Details of Support
①Preferential measures against regulations
②Tax support measures
③Financial support
④Monetary support

2. National Strategic Special Zones （May 2014）

Details of Support
①Preferential measures against regulations
②Tax support measures
③Financial support

National Project at KING SKYFRONT

1. Center Of Innovation Program (COI) (Oct. 2013)
INDUSTRY-ACADEMIA COLLABORATIVE R&D PROGRAMS

- R&D funding for a COI site is expected to maximum $10M per year.
- fy2013～fy2021



2. Regional Innovation and Ecosystem Formation Program (Jul. 2017)

- This program supports to create a successful model of industrialization with significant social impact based on global expansion from region.
- Grants of $1.55M per year.
- fy2017～fy2021



3. Research Complex Program(RCP) (Sep. 2015)

- RCP supports the construction of a mechanism producing continuous scientific and technological innovations in the regions
- Maximum $7M per year.
- fy2015～fy2019

“R&D” accumulation at KING SKYFRONT

57 organizations are located! (as of October ,2017)



Innovation Center of NanoMedicine (iCONM)

- A facility that can conduct everything from organic synthesis and microfabrication to biological experiments, all under one roof.
- Open innovation platform aiming for the realization/commercialization of innovative ideas
  - Nanomachines which can target and eliminate intractable cancer.
  - The system for in-home cancer diagnosis, which requires no blood sampling.
  - Social system for implementation of the results into society.



iCONM

Innovation Center of NanoMedicine

The "O" in the logo is designed after a nanomicelle, and the colour gradient toward the centre represents "infinite possibilities" and a "leap toward the future." The "winter blue" colour highlighted against the "black" of the surrounding letters represents "integrity" and "transparency."

Central Institute for Experimental Animals (CIEA)

In 1952, The Central Institute for Experimental Animals (CIEA) was founded.
CIEA has continued contributing to the health and welfare of humankind through the provision of quality laboratory animals with a high reproducible level, together with the establishment of sophisticated test method systems.

Working toward regenerative medicine for the central nerve system

In collaboration with Professor Hideyuki Okano, a professor in the Medical Department at Keio University, CIEA has conducted regenerative medicine research for remedy of spinal cord injury using iPS cells.



Hideyuki Okano, M.D.&ph.D.

Common Marmoset

2009
459 (7246) :523-7

NOG Mouse ／Humanized Mouse



Collaboration with Riken and the National Institute of Health and Sciences (NIHS)

●Riken: Collaboration with Dr. Katsuhiko Mikoshiba, Head of the Developmetal Neurobiology Laboratory and Senior Team Leader for Brain Science tests with marmosets

●NIHS – Pharmacology Department: Safety and efficacy tests for iPS-derived cardiac muscle cells

Katsuhiko Mikoshiba, M.D.&Ph.D.

National Institute of Health Sciences(NIHS)

【 Mission statement 】

The National Institute of Health Sciences (NIHS) is a National organizations, conducting Regulatory Science.
The results of these activities are passed on to the health and welfare administration and other organizations and other so that they may be reflected in national policies.

【History】

● In **1874,** The National Institute of Health Sciences (NIHS) was established in Tokyo as the Tokyo Drug Control Laboratory.

● In **1946**, the laboratory moved its office from Kanda Izumi-cho to its current location in Yoga.

● In **1997**, the laboratory reorganized to the NIHS.

Johnson & Johnson Tokyo science center

東京サイエンスセンター
TOKYO SCIENCE CENTER

Opened on Aug. 6th 2014 by Johnson & Johnson K.K. Medical Company.

- Built to promote safe and appropriate use of medical devices by healthcare professionals amid growing interest in minimally-invasive surgical procedures in Japan.
- Welcomed a medical staff of more than 22,000 people from Japan and abroad as of the end of July,2015
- Will contribute to the advancement of Japanese technology through the training of Japanese healthcare professionals.

PeptiDream INC.

- PeptiDream is a biopharmaceutical company that employs its proprietary Peptide Discovery Platform System (PDPS), a state-of-the-art highly versatile discovery platform which enables the production of highly diverse (trillions) non-standard peptides.
- Using the PDPS technology to develop peptide-based drugs—also known as the "third drug" after small-molecule and antibody based drugs—PeptiDream uses its PDPS system to work with its global and strategic/joint partners such as Novartis and GlaxoSmithKline

PeptiDream PEPTIDREAM INC. INNOVATIVE PEPTIDE THERAPEUTICS

Company Profile:
Founded: 2006
Capital: 3,630 million yen (June, 2016)

February, 2016
The 2nd Nippon Venture Award

CYBERDYNE

- CYBERDYNE has taken steps to secure itself as a hub for the innovative development of the medical business

- Cyberdyne, making full use of “Cybernics” - an integrated technology of human, robot and information systems, aims to both tackle/solve social issues via R&D and implementation of “innovative technology coexisting with people”, as well as to create a “New Industry” based on these solutions.

Comprehensive Agreement with Kawasaki City
(June 2014)

(1) Purpose

- Contribute to the solution of problems in the fields of the health, medical treatment, and welfare.

(2) Points of Cooperation

- Active introduction of robots for use in medical care, nursing, etc.
- Superior service through cooperation with industry/academia; promotion of product development
- Helping to develop cutting-edge medical enterprises through utilization of the advantages of the International Strategic Zone.

Life Innovation Center (LIC)

Object

The Center is located at Tonomachi area in Kawasaki City , where cutting-edge companies and Institutes related to lifescience field assemble. Utilizing this locational advantage and other factor , the Center will accelerate initiatives from R&D to commercialization for practical application and industrialization of promising seeds found in regenerative medicine and cell therapy.

Led by Kanagawa, the Center works closely with the national Government and global industries, utilizing merits of Special Zone.

As the hub of regenerative medicine & cell therapy, the Center Strongly supports tenants wishing to commercialize their projects.

4F Support for Venture Business

3F Laboratory and Office

2F Laboratory, Office and Clinic

1F Cell Culture, Produce and Processing

Introduction of a new R&D Lab and more by Daiwa House Co.





a Middle Molecule IT-based Drug Discovery Laboratory (MIDL) at KING SKYFORNT

東京工業大学
Tokyo Institute of Technology

慶應義塾
Keio University

Increasing Cooperation Between the Keihin Coastal Area and Haneda Airport

As the center of the International Strategic Zone,
Tokyo and Kawasaki will strengthen their cooperation in order to advance Japanese international competitiveness.

Construction of the Connection Road with Haneda Airport

Image of the Connection Road

Address 1 Miyamoto-cho Kawasaki-ku Kawasaki-city Kanagawa JAPAN

E-mail 59kokuse@city.kawasaki.jp

HP KING SKYFRONT, International Strategic Zone
http://inewsletter-king-skyfront.jp/en/

View of Kawasaki from Tokyo bay (Kawasaki on the left, Tama River in the middle, Tokyo on the right)